442 results about "Membrane protein" patented technology

A composition comprising (a) Neisseria meningitidis serogroup B outer membrane vesicles (OMVs), and (b) an immunogenic component selected from other Neisseria proteins, or immunogenic fragments thereof. Component (b) preferably includes a protein from a different NmB strain from that from which the OMV of component (a) is derived. The OMVs are preferably obtained by deoxycholate extraction. Optionally, the composition may also comprise a protective antigen against other pathogens.

An adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide is prepared to contain the component parts under a variety of conditions. The complex can be formulated with antigenic material to form immunogenic compositions, vaccines and immunotherapeutics. An induced immune response includes protective antibodies and/or type 1 cytokines is shown for a variety of protocols.

CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells and has been found on B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. Conversely, it is not found on hematopoietic stem cells, pro-B cells, differentiated plasma cells or non-lymphoid tissues. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). CD20 expressing cells are known to play a role in other diseases and disorders, including inflammation. The present invention includes anti-CD20 antibodies, forms and fragments, having superior physical and functional properties; immunoconjugates, compositions, diagnostic reagents, methods for inhibiting growth, therapeutic methods, improved antibodies and cell lines; and polynucleotides, vectors and genetic constructs encoding same.

The present invention relates to novel methods and compositions for detection and isolation of cancer cells with metastatic potential. The invention further relates to assays for measuring the metastatic potential of such cancer cells and drug screening assays for the identification of agents having anti-metastatic potential. The present invention further provides methods and compositions for inhibiting the metastatic potential of cancer cells by modulating the activity of serine integral membrane proteases [(SIMP) consisting of seprase and dipedidyl peptidase IV (DPPIV)]expressed on the surface of metastasizing cancer cells.

The invention discloses a fusion protein of a novel coronavirus envelope protein and an application of the fusion protein. The fusion protein (SARS2-RBD-Fc) is obtained by fusing an RBD structural domain of a novel coronavirus envelope protein S with an antibody Fc fragment; and as a subunit vaccine, the fusion protein can induce an organism to generate an efficient neutralizing antibody through nasal drip immunization and intramuscular injection. It indicates that the SARS2-RBD-Fc can be used as a candidate vaccine for preventing and treating new coronavirus infection.

The invention relates to enhancing translocation of a charged analyte through a transmembrane protein pore. Translocation is enhanced by increasing the net opposing charge of the barrel or channel and/or entrance of the pore. The invention also relates to pores enhanced in accordance with the invention.

This invention relates to a fusion protein used for preventing aftosa, its preparation method and application. This fusion protein contains O type foot-and-mouth disease virus main cytomembrane protein VP1 epitope, colibacillus thermolability toxin B subunit, thymus derived cell epitope and purification label.

A functional RNP containing negative-strand single-stranded RNA derived from Sendai virus, which has been modified so as not to express at least one envelope protein, has been successfully prepared. An RNP comprising a foreign gene is prepared and inserted into a cell with the use of a cationic liposome, thereby successfully expressing the foreign gene.

The invention relates to the production and use of retroviral vectors for cell specific gene transfer, specially to a production method of retroviral vectors containing capsid particles of murine leukemia virus (MLV) and envelope proteins of human immunodeficiency vises (HIV) or simian immunodeficiency viruses (SIV). Said vectors can be used for gene transfer in selected cell types, specially in CD4-positive mammal cells.

The invention discloses an anti-flavivirus envelope E protein monoclonal antibody and application thereof. The anti-flavivirus envelope E protein monoclonal antibody of the invention is secreted by a mouse source hybrid tumour cell strain D2-2A10G6 with the preservation number of CGMCC No. 3292. The anti-flavivirus monoclonal antibody of the invention can be specifically combined with the function epitope of flavivirus envelope E protein. The amino acid sequence of the functional epitope of envelope E protein is SEQ ID NO: 17. The monoclonal antibody of the invention is subject to screening by indirect immunofluorescent method, and indirect enzyme-linked immunization is used for evaluating the specificity and affinity when being combined with antigen. By adopting the monoclonal antibody or immunoconjugate of the invention, flavivirus infection cell can be blocked and suckling mouse can be protected from virus attack, thus achieving the effect of inhibiting virus infection. The monoclonal antibody or immunoconjugate of the invention also can be used for flavivirus envelope E protein detection.

The present invention relates to antibodies that bind phosphorylated forms of IRAK4, methods of using such antibodies to detect IRAK4 biological activity, and methods for the detection, diagnosis, and prognostication of pathological conditions related to IRAK4 biological activity. ERAK4 is one member of a small family of highly conserved cytoplasmic signal transduction proteins characterized by the presence of an N-terminal “death domain” and a C-terminal serine-threonine kinase domain. IRAK4 functions in cytoplasmic signal transduction pathways by interacting with membrane spanning proteins which play, inter alia, critical roles in vertebrate immune system function.

The present invention relates to construction of hepatitis B virus siRNA expression vector and its antiviral therapeutic application. According to the design principle said construction includes the following steps: respectively selecting nucleotide sequence of HBV envelope protein (MS) coding region 69nt-87nt, polymerase(p) coding region 708nt-726nt and core protein (c) coding region 2052 nt-2070nt, designing correspondent siRNA sequence, using BLAST software to analyze homogenously to confirm that it is HBV highly conservative sequence, then chemically synthesizing single-stranded oligonucleotide, external annearing to form double-stranded DNA, connecting it with eukaryotic expression vector pTZU6+1, enzyme excision identification and sequence determination and analysis show that siRNA extression vectors of three target hepatitis B virus (HBV) gene sequences are constructed. The tests show that HBV siRNA has the strong action of inhibiting virus replication and expression.

Synthetic HIV envelope proteins, vectors and compositions thereof, and methods for inducing protective immunity against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in vaccines to provide improved protective immunity against HIV.

The present invention is related to a method for blocking the infection of cells by dengue virus, based on interfering the direct interaction of the viral envelope protein with a cellular receptor or its indirect interaction with said cellular receptor through a carrier protein, as well as related uses; wherein said cellular receptor is the alpha-2 macroglobulin receptor, also known as the low density receptor-related protein or as CD91, and said carrier protein is human alpha-2 macroglobulin.

The invention discloses an mRNA vaccine and a synthesis method and a kit. The mRNA vaccine is prepared from an epitope antigen gene sequence of trimerical spike glycoprotein S, and/or an epitope antigen gene sequence of a transmembrane protein-envelope E, and/or, an epitope antigen gene sequence of membrane glycoprotein M, and/or, an epitope antigen gene sequence of nucleocapsid N, and/or, an epitope antigen gene sequence of a receptor binding domain (RBD) in the trimerical spike glycoprotein. According to the technical scheme of the invention, the mRNA vaccine is designed through a genetic engineering method so as to achieve immunity to the novel coronavirus.

The invention provides a serial cell-penetrating peptide modified tumor targeted and tumor penetrated nano drug delivery system capable of simultaneously identifying an integrin receptor and a transmembrane protein receptor, wherein the serial cell-penetrating peptide is mainly formed by connecting a DGR polypeptide fragment covalently at the C-tail end of polyarginine of the cell-penetrating peptide. The polypeptide not only can selectively identify two highly expressed receptors on the surfaces of the tumor cells, but also can be efficiently mediated into the cells. The nano drug delivery system mainly consists of a nano carrier, a drug and a lipid-polyethylene glycol-serial cell-penetrating peptide ligand interstitial compound and is a potential tumor targeted treatment carrier.

The invention relates to pseudo-virus. The pseudo-virus comprises a plasmid for expressing envelope protein Spike, a reporter gene plasmid and a packaging helper plasmid, wherein the plasmid for expressing the envelope protein Spike contains a CBA promoter and a human optimized Spike expression sequence, and is used for driving the expression of the envelope protein Spike. The pseudo-virus disclosed by the invention can simulate the process of infecting cells by wild novel coronavirus, can be used for researching the relationship between virus and host cells, cloning a receptor of virus and replacing a traditional neutralization test, and is used for researching differential diagnosis of diseases, evaluation and screening of antiviral drugs, evaluation of vaccine immune effect and the like. The invention also relates to a packaging method of the pseudo-virus and a novel coronavirus virus drug evaluation system containing the pseudo-virus, wherein the pseudo-virus is used for infectingthe 293T monoclonal cell which overexpresses the human ACE2 gene under the condition of drug interference, and by detecting the expression quantity of a reporter gene in the pseudo-virus (such as fluorescence intensity detection), the effectiveness of the drug is preliminarily evaluated.

A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Control of mammalian gastro-intestinal tissues growth and repair is facilitated by the use of the proteins, making the proteins candidates for therapies.